Dr Lawrence M Simons Sr, MD | |
7030 S Broadway St, Haysville, KS 67060-1471 | |
(316) 469-1099 | |
(316) 469-1098 |
Full Name | Dr Lawrence M Simons Sr |
---|---|
Gender | Male |
Speciality | Anesthesiology - Pain Medicine |
Location | 7030 S Broadway St, Haysville, Kansas |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1811961709 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | 0430198 (Kansas) | Primary |
207LP2900X | Anesthesiology - Pain Medicine | 0430198 (Kansas) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Lawrence M Simons Sr, MD 7030 S Broadway St, Haysville, KS 67060-1471 Ph: (316) 469-1099 | Dr Lawrence M Simons Sr, MD 7030 S Broadway St, Haysville, KS 67060-1471 Ph: (316) 469-1099 |
News Archive
Results from the initial clinical trial of the ClariVein® catheter, used in a new minimally invasive treatment for varicose veins, have been announced. The device combines mechanical and chemical modalities to accomplish vein treatment in an in-office setting.
In a recent medRxiv research paper, the US scientists examined the effects of non-synonymous mutations in the circulating B.1.1.7 strain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on linear antibody epitope signal for viral spike glycoprotein and nucleoprotein – and demonstrated that mutations should not result in immune evasion.
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.
It has been more than 50 years since the U.S. Food and Drug Administration (FDA) last approved a new medicine specifically for lupus – when Dwight D. Eisenhower was president. Existing treatments have been "borrowed" from other disorders and the risk/benefit ratio of these treatments is far from optimal. However, hope is on the horizon.
› Verified 3 days ago